BR112019005587A2 - proteínas de ligação recombinantes e sua utilização - Google Patents
proteínas de ligação recombinantes e sua utilizaçãoInfo
- Publication number
- BR112019005587A2 BR112019005587A2 BR112019005587A BR112019005587A BR112019005587A2 BR 112019005587 A2 BR112019005587 A2 BR 112019005587A2 BR 112019005587 A BR112019005587 A BR 112019005587A BR 112019005587 A BR112019005587 A BR 112019005587A BR 112019005587 A2 BR112019005587 A2 BR 112019005587A2
- Authority
- BR
- Brazil
- Prior art keywords
- binding proteins
- recombinant binding
- nucleic acids
- recombinant
- pharmaceutical compositions
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 6
- 108091008324 binding proteins Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000008102 Ankyrins Human genes 0.000 abstract 1
- 108010049777 Ankyrins Proteins 0.000 abstract 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- -1 acids nucleic acids Chemical class 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"proteínas de ligação recombinantes e sua utilização" são divulgadas novas proteínas de ligação recombinante, incluindo domínios projetados de repetição de anquirina com especificidade de ligação para her2, e incluindo domínios projetados de repetição de anquirina com especificidade de ligação para albumina sérica, bem como ácidos nucleicos que codificam essas proteínas de ligação recombinante, composições farmacêuticas que incluem tais proteínas de ligação recombinante ou ácidos nucleicos e a utilização dessas proteínas de ligação recombinante, ácidos nucleicos ou composições farmacêuticas no tratamento de doenças.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190221 | 2016-09-22 | ||
| PCT/EP2017/073768 WO2018054971A1 (en) | 2016-09-22 | 2017-09-20 | Recombinant binding proteins and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005587A2 true BR112019005587A2 (pt) | 2019-06-11 |
Family
ID=57046984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005587A BR112019005587A2 (pt) | 2016-09-22 | 2017-09-20 | proteínas de ligação recombinantes e sua utilização |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10717772B2 (pt) |
| EP (1) | EP3515933B9 (pt) |
| JP (1) | JP6976335B2 (pt) |
| KR (1) | KR102270315B1 (pt) |
| CN (1) | CN109790206A (pt) |
| AR (1) | AR109680A1 (pt) |
| AU (1) | AU2017331329B2 (pt) |
| BR (1) | BR112019005587A2 (pt) |
| CA (1) | CA3036301C (pt) |
| CL (1) | CL2019000729A1 (pt) |
| CO (1) | CO2019002609A2 (pt) |
| ES (1) | ES2953516T3 (pt) |
| IL (1) | IL265489B (pt) |
| MX (1) | MX2019003298A (pt) |
| MY (1) | MY196882A (pt) |
| NZ (1) | NZ751689A (pt) |
| PH (1) | PH12019500596A1 (pt) |
| SA (1) | SA519401369B1 (pt) |
| WO (1) | WO2018054971A1 (pt) |
| ZA (1) | ZA201901592B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220016942A (ko) * | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 재조합 fap 결합 단백질 및 이의 용도 |
| US20240124535A1 (en) | 2019-06-04 | 2024-04-18 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| CA3139051A1 (en) | 2019-06-04 | 2020-12-10 | Christian REICHEN | Multispecific proteins |
| WO2021116462A1 (en) | 2019-12-11 | 2021-06-17 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| AU2021267411A1 (en) | 2020-05-06 | 2022-12-08 | Molecular Partners Ag | Novel ankyrin repeat binding proteins and their uses |
| WO2021229067A1 (en) | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Multispecific proteins |
| AU2021271131A1 (en) * | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
| CA3202358A1 (en) | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
| JP2024509241A (ja) | 2021-03-09 | 2024-02-29 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のＤＡＲＰｉｎに基づくＣＤ１２３エンゲージャ |
| BR112023018293A2 (pt) | 2021-03-09 | 2023-10-31 | Molecular Partners Ag | Acopladores de célula t multiespecíficos à base de darpin |
| JP2024508969A (ja) | 2021-03-09 | 2024-02-28 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ |
| AU2022232216A1 (en) | 2021-03-09 | 2023-10-05 | Molecular Partners Ag | Protease cleavable prodrugs |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| WO2024028278A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| WO2003018611A2 (en) * | 2001-08-24 | 2003-03-06 | University Of Victoria Innovation And Development Corporation | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| EP2292246A1 (en) | 2004-11-12 | 2011-03-09 | Bayer Schering Pharma Aktiengesellschaft | Recombinant Newcastle Disease Virus |
| ATE448305T1 (de) | 2005-07-08 | 2009-11-15 | Univ Zuerich | Phagen-display mittels cotranslationaler translokation von fusionspolypeptiden |
| US9365629B2 (en) | 2007-09-24 | 2016-06-14 | University Of Zurich | Designed armadillo repeat proteins |
| EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| EP2358746B1 (en) | 2008-11-03 | 2020-09-16 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| KR20140032356A (ko) * | 2010-11-26 | 2014-03-14 | 몰리큘라 파트너스 아게 | 설계된 안키린 반복 단백질에 대한 개선된 n-말단 캡핑 모듈 |
| WO2012149439A2 (en) | 2011-04-29 | 2012-11-01 | Janssen Biotech, Inc. | Il4/il13 binding repeat proteins and uses |
| CN104508129A (zh) | 2012-06-28 | 2015-04-08 | 分子伴侣公司 | 设计的与血小板衍生生长因子结合的锚蛋白重复序列蛋白 |
| JP2015532306A (ja) | 2012-10-15 | 2015-11-09 | チューリッヒ大学 | 癌治療のための二重特異性ｈｅｒ２リガンド |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US11453708B2 (en) | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
| IL276944B (en) * | 2015-04-02 | 2022-07-01 | Molecular Partners Ag | Designed regions containing ankyrin repeats with specific binding to serum albumin |
-
2017
- 2017-09-20 CN CN201780058511.0A patent/CN109790206A/zh active Pending
- 2017-09-20 BR BR112019005587A patent/BR112019005587A2/pt unknown
- 2017-09-20 AR ARP170102593A patent/AR109680A1/es unknown
- 2017-09-20 KR KR1020197009396A patent/KR102270315B1/ko active IP Right Grant
- 2017-09-20 US US15/710,001 patent/US10717772B2/en active Active
- 2017-09-20 JP JP2019536693A patent/JP6976335B2/ja active Active
- 2017-09-20 CA CA3036301A patent/CA3036301C/en active Active
- 2017-09-20 ES ES17778226T patent/ES2953516T3/es active Active
- 2017-09-20 MY MYPI2019001523A patent/MY196882A/en unknown
- 2017-09-20 MX MX2019003298A patent/MX2019003298A/es active IP Right Grant
- 2017-09-20 NZ NZ751689A patent/NZ751689A/en unknown
- 2017-09-20 EP EP17778226.5A patent/EP3515933B9/en active Active
- 2017-09-20 AU AU2017331329A patent/AU2017331329B2/en active Active
- 2017-09-20 WO PCT/EP2017/073768 patent/WO2018054971A1/en unknown
-
2019
- 2019-03-14 ZA ZA2019/01592A patent/ZA201901592B/en unknown
- 2019-03-19 IL IL265489A patent/IL265489B/en unknown
- 2019-03-19 PH PH12019500596A patent/PH12019500596A1/en unknown
- 2019-03-20 SA SA519401369A patent/SA519401369B1/ar unknown
- 2019-03-21 CL CL2019000729A patent/CL2019000729A1/es unknown
- 2019-03-21 CO CONC2019/0002609A patent/CO2019002609A2/es unknown
-
2020
- 2020-06-22 US US16/907,415 patent/US20210130420A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180155402A1 (en) | 2018-06-07 |
| RU2019111628A3 (pt) | 2020-10-30 |
| EP3515933A1 (en) | 2019-07-31 |
| KR20190050802A (ko) | 2019-05-13 |
| EP3515933B1 (en) | 2023-06-07 |
| CN109790206A (zh) | 2019-05-21 |
| EP3515933B9 (en) | 2023-08-16 |
| KR102270315B1 (ko) | 2021-06-29 |
| AU2017331329A1 (en) | 2019-04-04 |
| MY196882A (en) | 2023-05-08 |
| NZ751689A (en) | 2021-07-30 |
| PH12019500596A1 (en) | 2019-07-29 |
| AR109680A1 (es) | 2019-01-09 |
| MX2019003298A (es) | 2019-09-26 |
| US10717772B2 (en) | 2020-07-21 |
| JP2019531093A (ja) | 2019-10-31 |
| ZA201901592B (en) | 2021-04-28 |
| CO2019002609A2 (es) | 2019-05-31 |
| CA3036301C (en) | 2021-04-20 |
| WO2018054971A1 (en) | 2018-03-29 |
| EP3515933C0 (en) | 2023-06-07 |
| RU2019111628A (ru) | 2020-10-19 |
| ES2953516T3 (es) | 2023-11-14 |
| IL265489B (en) | 2021-07-29 |
| US20210130420A1 (en) | 2021-05-06 |
| CL2019000729A1 (es) | 2019-06-14 |
| IL265489A (en) | 2019-05-30 |
| JP6976335B2 (ja) | 2021-12-08 |
| CA3036301A1 (en) | 2018-03-29 |
| SA519401369B1 (ar) | 2022-12-22 |
| AU2017331329B2 (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| BR112019023856A2 (pt) | proteínas triespecíficas que visam msln e métodos de utilização | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| PH12017501792A1 (en) | Recombinant binding proteins and their use | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| MX2020011257A (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| MX2022007122A (es) | Dominios de repetición de anquirina diseñados con residuos de superficie alterados. | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
| BR112019006887A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias | |
| EA201990689A1 (ru) | Бактериальные мини-клетки для доставки адъювантов на основе нуклеиновых кислот и способы их применения | |
| MX2020009507A (es) | Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos. | |
| EA201991181A1 (ru) | Psma-нацеленные триспецифические белки и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |